The ASCO Post
@ascopost.bsky.social
News and views from the world of clinical oncology and hematology
🥫 Study highlights possible links between select food preservatives and cancer risk:
• Potassium sorbate, potassium nitrate, total acetates → ⬆️ overall & breast cancer risk
• Sodium nitrite → ⬆️ prostate cancer risk
🔹Hasenböhler et al |
https://ow.ly/oJlT50XWc7r
• Potassium sorbate, potassium nitrate, total acetates → ⬆️ overall & breast cancer risk
• Sodium nitrite → ⬆️ prostate cancer risk
🔹Hasenböhler et al |
https://ow.ly/oJlT50XWc7r
January 13, 2026 at 6:15 PM
🥫 Study highlights possible links between select food preservatives and cancer risk:
• Potassium sorbate, potassium nitrate, total acetates → ⬆️ overall & breast cancer risk
• Sodium nitrite → ⬆️ prostate cancer risk
🔹Hasenböhler et al |
https://ow.ly/oJlT50XWc7r
• Potassium sorbate, potassium nitrate, total acetates → ⬆️ overall & breast cancer risk
• Sodium nitrite → ⬆️ prostate cancer risk
🔹Hasenböhler et al |
https://ow.ly/oJlT50XWc7r
📊 Final data from phase III AGO-OVAR 2.29:
No significant OS or PFS benefit with atezolizumab + bevacizumab + nonplatinum chemo in recurrent ovarian cancer, though a paclitaxel subgroup showed a favorable OS signal.
🔸 Philipp Harter, MD
🔗 https://ow.ly/PYjn50XVIWN
No significant OS or PFS benefit with atezolizumab + bevacizumab + nonplatinum chemo in recurrent ovarian cancer, though a paclitaxel subgroup showed a favorable OS signal.
🔸 Philipp Harter, MD
🔗 https://ow.ly/PYjn50XVIWN
January 12, 2026 at 9:45 PM
📊 Final data from phase III AGO-OVAR 2.29:
No significant OS or PFS benefit with atezolizumab + bevacizumab + nonplatinum chemo in recurrent ovarian cancer, though a paclitaxel subgroup showed a favorable OS signal.
🔸 Philipp Harter, MD
🔗 https://ow.ly/PYjn50XVIWN
No significant OS or PFS benefit with atezolizumab + bevacizumab + nonplatinum chemo in recurrent ovarian cancer, though a paclitaxel subgroup showed a favorable OS signal.
🔸 Philipp Harter, MD
🔗 https://ow.ly/PYjn50XVIWN
🔬COMMIT trial shows triplet therapy (FOLFOX + bevacizumab + atezolizumab) significantly improved PFS vs atezolizumab alone in 1L dMMR/MSI-H mCRC (HR = 0.43)
• 12-mo PFS: 67% vs 35%
Caio Max Sao Pedro Rocha Lima, MD, MS
🔗 https://ow.ly/Mpgl50XT5Yw
• 12-mo PFS: 67% vs 35%
Caio Max Sao Pedro Rocha Lima, MD, MS
🔗 https://ow.ly/Mpgl50XT5Yw
January 8, 2026 at 10:15 PM
🔬COMMIT trial shows triplet therapy (FOLFOX + bevacizumab + atezolizumab) significantly improved PFS vs atezolizumab alone in 1L dMMR/MSI-H mCRC (HR = 0.43)
• 12-mo PFS: 67% vs 35%
Caio Max Sao Pedro Rocha Lima, MD, MS
🔗 https://ow.ly/Mpgl50XT5Yw
• 12-mo PFS: 67% vs 35%
Caio Max Sao Pedro Rocha Lima, MD, MS
🔗 https://ow.ly/Mpgl50XT5Yw
🍔A study found higher fast-food spending by block in Alabama was linked to more cases of early-onset colorectal cancer, while higher fruit & vegetable spending had a strong protective effect.🥦
🔹 Blake Buchalter, MPH, PhD
🔗 https://ow.ly/urH650XT29I
🔹 Blake Buchalter, MPH, PhD
🔗 https://ow.ly/urH650XT29I
January 7, 2026 at 8:45 PM
🍔A study found higher fast-food spending by block in Alabama was linked to more cases of early-onset colorectal cancer, while higher fruit & vegetable spending had a strong protective effect.🥦
🔹 Blake Buchalter, MPH, PhD
🔗 https://ow.ly/urH650XT29I
🔹 Blake Buchalter, MPH, PhD
🔗 https://ow.ly/urH650XT29I
🔮 The path forward isn’t AI instead of clinicians—but human+AI collaboration, according to Michael Sobolev, PhD et al.
🔹 Public trust, including for AI’s role in #cancer detection (currently ~15% of survey respondents), grows with experience.
🔗 https://ow.ly/EOYs50XS1A7
🔹 Public trust, including for AI’s role in #cancer detection (currently ~15% of survey respondents), grows with experience.
🔗 https://ow.ly/EOYs50XS1A7
January 6, 2026 at 11:15 PM
🔮 The path forward isn’t AI instead of clinicians—but human+AI collaboration, according to Michael Sobolev, PhD et al.
🔹 Public trust, including for AI’s role in #cancer detection (currently ~15% of survey respondents), grows with experience.
🔗 https://ow.ly/EOYs50XS1A7
🔹 Public trust, including for AI’s role in #cancer detection (currently ~15% of survey respondents), grows with experience.
🔗 https://ow.ly/EOYs50XS1A7
🔬Postoperative ctDNA testing may help personalize adjuvant therapy in patients with colon cancer—identifying those most likely to benefit from NSAIDs like celecoxib added to chemotherapy.
👨⚕️ George Q. Zhang, MD, MPH
🔗 https://ow.ly/XuPs50XS1p3
👨⚕️ George Q. Zhang, MD, MPH
🔗 https://ow.ly/XuPs50XS1p3
January 6, 2026 at 7:25 PM
🔬Postoperative ctDNA testing may help personalize adjuvant therapy in patients with colon cancer—identifying those most likely to benefit from NSAIDs like celecoxib added to chemotherapy.
👨⚕️ George Q. Zhang, MD, MPH
🔗 https://ow.ly/XuPs50XS1p3
👨⚕️ George Q. Zhang, MD, MPH
🔗 https://ow.ly/XuPs50XS1p3
📊Phase III inMIND trial: Adding tafasitamab to lenalidomide + rituximab significantly improved PFS in patients with relapsed/refractory Follicular Lymphoma (22.4 vs 13.9 months; HR = 0.43).
🔺Laurie H. Sehn, MD
🔗 https://ow.ly/PYBQ50XS1kF
🔺Laurie H. Sehn, MD
🔗 https://ow.ly/PYBQ50XS1kF
January 6, 2026 at 3:01 PM
📊Phase III inMIND trial: Adding tafasitamab to lenalidomide + rituximab significantly improved PFS in patients with relapsed/refractory Follicular Lymphoma (22.4 vs 13.9 months; HR = 0.43).
🔺Laurie H. Sehn, MD
🔗 https://ow.ly/PYBQ50XS1kF
🔺Laurie H. Sehn, MD
🔗 https://ow.ly/PYBQ50XS1kF
New meta-analysis shows that GLP-1 receptor agonists likely have little or no effect on obesity-related #cancer risk.
Longer-term, cancer-specific studies still needed.
🔸Ko et al
🔗 https://ascopost.com/news/december-2025/study-explores-association-of-glp-1-ras-with-risk-of-obesity-related-cancers/
Longer-term, cancer-specific studies still needed.
🔸Ko et al
🔗 https://ascopost.com/news/december-2025/study-explores-association-of-glp-1-ras-with-risk-of-obesity-related-cancers/
January 5, 2026 at 5:20 PM
New meta-analysis shows that GLP-1 receptor agonists likely have little or no effect on obesity-related #cancer risk.
Longer-term, cancer-specific studies still needed.
🔸Ko et al
🔗 https://ascopost.com/news/december-2025/study-explores-association-of-glp-1-ras-with-risk-of-obesity-related-cancers/
Longer-term, cancer-specific studies still needed.
🔸Ko et al
🔗 https://ascopost.com/news/december-2025/study-explores-association-of-glp-1-ras-with-risk-of-obesity-related-cancers/
🩸 Potential new standard of care in newly diagnosed Multiple Myeloma
ADVANCE trial from ASCO25: Adding daratumumab to KRd significantly improved MRD negativity vs KRd alone—without added toxicity in selected patients.
👨⚕️ C. Ola Landgren, MD, PhD
🔗 https://ow.ly/Cx2L50XNJ7S
ADVANCE trial from ASCO25: Adding daratumumab to KRd significantly improved MRD negativity vs KRd alone—without added toxicity in selected patients.
👨⚕️ C. Ola Landgren, MD, PhD
🔗 https://ow.ly/Cx2L50XNJ7S
January 2, 2026 at 9:00 PM
🩸 Potential new standard of care in newly diagnosed Multiple Myeloma
ADVANCE trial from ASCO25: Adding daratumumab to KRd significantly improved MRD negativity vs KRd alone—without added toxicity in selected patients.
👨⚕️ C. Ola Landgren, MD, PhD
🔗 https://ow.ly/Cx2L50XNJ7S
ADVANCE trial from ASCO25: Adding daratumumab to KRd significantly improved MRD negativity vs KRd alone—without added toxicity in selected patients.
👨⚕️ C. Ola Landgren, MD, PhD
🔗 https://ow.ly/Cx2L50XNJ7S
Happy New Year from The ASCO Post!
January 1, 2026 at 3:01 PM
Happy New Year from The ASCO Post!
🔬 TAP Highlight of 2025: Is this the end of cancer research as we know it?
A proposed 15% cap on NIH indirect (F&A) costs threatens labs, clinical trials, and decades of progress in #CancerResearch—jeopardizing patients and innovation nationwide.
🔗 https://ow.ly/IGA850XNJ41
A proposed 15% cap on NIH indirect (F&A) costs threatens labs, clinical trials, and decades of progress in #CancerResearch—jeopardizing patients and innovation nationwide.
🔗 https://ow.ly/IGA850XNJ41
December 31, 2025 at 7:00 PM
🔬 TAP Highlight of 2025: Is this the end of cancer research as we know it?
A proposed 15% cap on NIH indirect (F&A) costs threatens labs, clinical trials, and decades of progress in #CancerResearch—jeopardizing patients and innovation nationwide.
🔗 https://ow.ly/IGA850XNJ41
A proposed 15% cap on NIH indirect (F&A) costs threatens labs, clinical trials, and decades of progress in #CancerResearch—jeopardizing patients and innovation nationwide.
🔗 https://ow.ly/IGA850XNJ41
#YearInReview: In matched-related donor stem cell transplantation, cyclophosphamide + calcineurin inhibition significantly improved GVHD- & relapse-free survival vs standard therapy—without added toxicity. From #EHA25
🔸 David Curtis, MBBS, PhD
🔗 https://ow.ly/ZfQ450XNJ1R
🔸 David Curtis, MBBS, PhD
🔗 https://ow.ly/ZfQ450XNJ1R
December 30, 2025 at 2:01 PM
#YearInReview: In matched-related donor stem cell transplantation, cyclophosphamide + calcineurin inhibition significantly improved GVHD- & relapse-free survival vs standard therapy—without added toxicity. From #EHA25
🔸 David Curtis, MBBS, PhD
🔗 https://ow.ly/ZfQ450XNJ1R
🔸 David Curtis, MBBS, PhD
🔗 https://ow.ly/ZfQ450XNJ1R
TAP Highlight of 2025 - Update in early HER2+ Breast Cancer:
• Adjuvant: T-DXd beat T-DM1 in high-risk residual disease (HR = 0.47)
• Neoadjuvant: T-DXd→THP improved pCR (67.3% vs 56.3%)
• Signals for fewer CNS events (DB05)
🔗 https://ow.ly/3BCO50XNIRO
• Adjuvant: T-DXd beat T-DM1 in high-risk residual disease (HR = 0.47)
• Neoadjuvant: T-DXd→THP improved pCR (67.3% vs 56.3%)
• Signals for fewer CNS events (DB05)
🔗 https://ow.ly/3BCO50XNIRO
December 29, 2025 at 4:45 PM
TAP Highlight of 2025 - Update in early HER2+ Breast Cancer:
• Adjuvant: T-DXd beat T-DM1 in high-risk residual disease (HR = 0.47)
• Neoadjuvant: T-DXd→THP improved pCR (67.3% vs 56.3%)
• Signals for fewer CNS events (DB05)
🔗 https://ow.ly/3BCO50XNIRO
• Adjuvant: T-DXd beat T-DM1 in high-risk residual disease (HR = 0.47)
• Neoadjuvant: T-DXd→THP improved pCR (67.3% vs 56.3%)
• Signals for fewer CNS events (DB05)
🔗 https://ow.ly/3BCO50XNIRO
🚨 ICYMI: NCCN early 2025 updates impacted practice across:
• 🫙 Bladder: periop/sandwich IO + chemo; HER2-targeted options
• 🫁 NSCLC/SCLC: more periop + consolidation IO; tarlatamab added
• 🧬 mCRC: expanded IO + BRAF-targeted combos
• 🩸 Myeloma: quadruplets gaining ground
🔗 https://ow.ly/1j7j50XNIzM
• 🫙 Bladder: periop/sandwich IO + chemo; HER2-targeted options
• 🫁 NSCLC/SCLC: more periop + consolidation IO; tarlatamab added
• 🧬 mCRC: expanded IO + BRAF-targeted combos
• 🩸 Myeloma: quadruplets gaining ground
🔗 https://ow.ly/1j7j50XNIzM
December 26, 2025 at 7:00 PM
🚨 ICYMI: NCCN early 2025 updates impacted practice across:
• 🫙 Bladder: periop/sandwich IO + chemo; HER2-targeted options
• 🫁 NSCLC/SCLC: more periop + consolidation IO; tarlatamab added
• 🧬 mCRC: expanded IO + BRAF-targeted combos
• 🩸 Myeloma: quadruplets gaining ground
🔗 https://ow.ly/1j7j50XNIzM
• 🫙 Bladder: periop/sandwich IO + chemo; HER2-targeted options
• 🫁 NSCLC/SCLC: more periop + consolidation IO; tarlatamab added
• 🧬 mCRC: expanded IO + BRAF-targeted combos
• 🩸 Myeloma: quadruplets gaining ground
🔗 https://ow.ly/1j7j50XNIzM
Wishing you a wonderful holiday season!
December 25, 2025 at 5:01 PM
Wishing you a wonderful holiday season!
👉 Major takeaways from Treatment Advances in Malignant Hematology from NCCNhem25:
• Immunotherapy-first strategies expanding
• MRD driving treatment intensity
• Biomarkers guiding frontline choices
• Outpatient management of cellular therapies
🔗 https://ow.ly/bU3350XNIyw
• Immunotherapy-first strategies expanding
• MRD driving treatment intensity
• Biomarkers guiding frontline choices
• Outpatient management of cellular therapies
🔗 https://ow.ly/bU3350XNIyw
December 24, 2025 at 4:02 PM
👉 Major takeaways from Treatment Advances in Malignant Hematology from NCCNhem25:
• Immunotherapy-first strategies expanding
• MRD driving treatment intensity
• Biomarkers guiding frontline choices
• Outpatient management of cellular therapies
🔗 https://ow.ly/bU3350XNIyw
• Immunotherapy-first strategies expanding
• MRD driving treatment intensity
• Biomarkers guiding frontline choices
• Outpatient management of cellular therapies
🔗 https://ow.ly/bU3350XNIyw
Deb Schrag, MD, MPH, has been chosen as the American Society of Clinical Oncology President for 2027–2028
The new Board of Directors and Nominating Committee Members have also been chosen. They will start their terms after the 2026 ASCO Annual Meeting.
🔗https://ow.ly/8Ve050XNLay
The new Board of Directors and Nominating Committee Members have also been chosen. They will start their terms after the 2026 ASCO Annual Meeting.
🔗https://ow.ly/8Ve050XNLay
Deb Schrag, MD, MPH, FASCO, Elected 2027–2028 ASCO President
Dr. Schrag, a gastrointestinal medical oncologist, is the George J. Bosl Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill Cornell Medica...
ow.ly
December 23, 2025 at 8:45 PM
Deb Schrag, MD, MPH, has been chosen as the American Society of Clinical Oncology President for 2027–2028
The new Board of Directors and Nominating Committee Members have also been chosen. They will start their terms after the 2026 ASCO Annual Meeting.
🔗https://ow.ly/8Ve050XNLay
The new Board of Directors and Nominating Committee Members have also been chosen. They will start their terms after the 2026 ASCO Annual Meeting.
🔗https://ow.ly/8Ve050XNLay
🫂 When doctors are the family members, the words hit differently. Filipe Coutinho, MD, reflects on navigating cancer not as a clinician, but as a loved one, and how it reshaped his approach to care.
✍️ Filipe Coutinho, MD
🔗 https://ow.ly/iJBZ50XNhSz
✍️ Filipe Coutinho, MD
🔗 https://ow.ly/iJBZ50XNhSz
December 23, 2025 at 5:30 PM
🫂 When doctors are the family members, the words hit differently. Filipe Coutinho, MD, reflects on navigating cancer not as a clinician, but as a loved one, and how it reshaped his approach to care.
✍️ Filipe Coutinho, MD
🔗 https://ow.ly/iJBZ50XNhSz
✍️ Filipe Coutinho, MD
🔗 https://ow.ly/iJBZ50XNhSz
🏥 Dana-Farber Cancer Institute's Neuro-Inclusive Oncology Care & Empowerment Program is rethinking #cancercare for patients with intellectual and developmental disabilities—prioritizing communication, sensory needs, and workforce training.
✍️ Melissa Levin, MSW, LICSW
🔗 https://ow.ly/yBzM50XNfIJ
✍️ Melissa Levin, MSW, LICSW
🔗 https://ow.ly/yBzM50XNfIJ
December 22, 2025 at 7:30 PM
🏥 Dana-Farber Cancer Institute's Neuro-Inclusive Oncology Care & Empowerment Program is rethinking #cancercare for patients with intellectual and developmental disabilities—prioritizing communication, sensory needs, and workforce training.
✍️ Melissa Levin, MSW, LICSW
🔗 https://ow.ly/yBzM50XNfIJ
✍️ Melissa Levin, MSW, LICSW
🔗 https://ow.ly/yBzM50XNfIJ
💡 For women with BRCA1/2 mutations facing surgical menopause: new prospective data suggest menopausal hormone therapy can be used without increasing #breastcancer risk.
Joanne Kotsopoulos, PhD | #SABCS25
Learn more: https://ow.ly/Pcs250XKAqj
Joanne Kotsopoulos, PhD | #SABCS25
Learn more: https://ow.ly/Pcs250XKAqj
December 17, 2025 at 9:25 PM
💡 For women with BRCA1/2 mutations facing surgical menopause: new prospective data suggest menopausal hormone therapy can be used without increasing #breastcancer risk.
Joanne Kotsopoulos, PhD | #SABCS25
Learn more: https://ow.ly/Pcs250XKAqj
Joanne Kotsopoulos, PhD | #SABCS25
Learn more: https://ow.ly/Pcs250XKAqj
Routine liquid biopsy screening for multiple cancers could cut late-stage cancer diagnoses nearly in half, per new modeling data of 14 cancer types. Earlier detection may significantly improve outcomes and reduce disease burden.
🔷 Chhatwal et al
https://ow.ly/IIKj50XA802
🔷 Chhatwal et al
https://ow.ly/IIKj50XA802
December 5, 2025 at 4:00 PM
Routine liquid biopsy screening for multiple cancers could cut late-stage cancer diagnoses nearly in half, per new modeling data of 14 cancer types. Earlier detection may significantly improve outcomes and reduce disease burden.
🔷 Chhatwal et al
https://ow.ly/IIKj50XA802
🔷 Chhatwal et al
https://ow.ly/IIKj50XA802
Catch up on all of the highlights from ESMO Congress 2025!
Dive into the latest breakthroughs in oncology in this #ESMO25-focused supplement from The ASCO Post including updates across immunotherapy, targeted treatments, and biomarkers.
🔗 https://ow.ly/JWtN50XA8rm
Dive into the latest breakthroughs in oncology in this #ESMO25-focused supplement from The ASCO Post including updates across immunotherapy, targeted treatments, and biomarkers.
🔗 https://ow.ly/JWtN50XA8rm
December 4, 2025 at 5:00 PM
Catch up on all of the highlights from ESMO Congress 2025!
Dive into the latest breakthroughs in oncology in this #ESMO25-focused supplement from The ASCO Post including updates across immunotherapy, targeted treatments, and biomarkers.
🔗 https://ow.ly/JWtN50XA8rm
Dive into the latest breakthroughs in oncology in this #ESMO25-focused supplement from The ASCO Post including updates across immunotherapy, targeted treatments, and biomarkers.
🔗 https://ow.ly/JWtN50XA8rm
🆕 American Cancer Society Cancer Action Network study shows patients with cancer increasingly turn to crowdfunding for expenses. Only 11.5% of campaigns meet their goals, revealing major gaps in affordability and financial assistance #CostsofCare
🔸Zhiyuan Zheng, PhD
🔗 https://ow.ly/GUXl50XA883
🔸Zhiyuan Zheng, PhD
🔗 https://ow.ly/GUXl50XA883
December 2, 2025 at 6:30 PM
🆕 American Cancer Society Cancer Action Network study shows patients with cancer increasingly turn to crowdfunding for expenses. Only 11.5% of campaigns meet their goals, revealing major gaps in affordability and financial assistance #CostsofCare
🔸Zhiyuan Zheng, PhD
🔗 https://ow.ly/GUXl50XA883
🔸Zhiyuan Zheng, PhD
🔗 https://ow.ly/GUXl50XA883
The November 25 issue of The ASCO Post features insights from ESMO 2025, ASTRO 2025, NCCNhem 2025; perspectives on the AI era changing health care, cancer survivor concerns of health care costs, and MORE.
Read the full issue 👉 https://ascopost.com/issues/november-25-2025/
Read the full issue 👉 https://ascopost.com/issues/november-25-2025/
December 1, 2025 at 8:01 PM
The November 25 issue of The ASCO Post features insights from ESMO 2025, ASTRO 2025, NCCNhem 2025; perspectives on the AI era changing health care, cancer survivor concerns of health care costs, and MORE.
Read the full issue 👉 https://ascopost.com/issues/november-25-2025/
Read the full issue 👉 https://ascopost.com/issues/november-25-2025/
🔬New CAPS analysis: Mild dilation of the main pancreatic duct is an independent risk factor for progression to pancreatic cancer in high-risk individuals. Risk reached 16% at 5 yrs and 26% at 10 yrs.
✍️ Marcia Irene Canto, MD, MHS
🔗 https://ow.ly/RnRA50XukBo
✍️ Marcia Irene Canto, MD, MHS
🔗 https://ow.ly/RnRA50XukBo
November 21, 2025 at 5:15 PM
🔬New CAPS analysis: Mild dilation of the main pancreatic duct is an independent risk factor for progression to pancreatic cancer in high-risk individuals. Risk reached 16% at 5 yrs and 26% at 10 yrs.
✍️ Marcia Irene Canto, MD, MHS
🔗 https://ow.ly/RnRA50XukBo
✍️ Marcia Irene Canto, MD, MHS
🔗 https://ow.ly/RnRA50XukBo